Skip to main content
OpenTrials
Completed

NCT Number: NCT04290052

Atrial Fibrillation After PFO Closure

An increased risk of atrial fibrillation (AF) after patent foramen ovale (PFO) closure was observed in randomized trials but systematic screening of AF was not performed in these studies. Purpose: The objective of this study was to evaluate incidence of AF in patients who underwent percutaneous PFO closure with serial 24-hours ambulatory ECG (AECG) monitoring during 6 months follow-up. Primary endpoint was incidence of AF on ECG monitoring. Secondary endpoints were clinical outcomes (symptoms, hospitalization from cardiovascular causes, ischemic stroke, or bleeding) up to 6 month follow-up.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Uhmontpellier

Montpellier, 34295, France

About this study

This is a prospective, bicentric, observational cohort study which will be performed in University hospital center of Montpellier and Nîmes The study will include all consecutive patients, admitted for a percutaneous PFO closure after an ischemic stroke (IS) or a transient ischemic attack (TIA) of cryptogenic origin, or after the occurrence of a decompression illness during scuba diving. Patients eligible for the closure of a FOP in prevention of the recurrence of stroke or TIA of cryptogenic origin, was systematically evaluated for exclusion of supraventricular arrhythmia in accordance with international recommendations. This evaluation included a 12-lead ECG as well as an extended electrocardiographic monitoring lasting more than or equal to 24 hours (most frequently, performing a 72-hour ECG Holter). All patients previously has a transesophageal ultrasound (TEE) allowing to retain the diagnosis of PFO, to assess the presence or not of an atrial septum aneurysm (ASA) associated with PFO and to quantify the right to left shunt thanks to a contrast test potentiated by a Valsalva maneuver. Exclusion criteria included interatrial defect with left to right and others indications for PFO closure that cryptogenic stroke or decompression illness. Indication of PFO closure is always validated by a cardio neurological team.

The primary objective of the study was incidence of AF defined as an irregular rhythm without discernible P waves lasting at least 30 seconds on ECG monitoring during the 6-month follow-up. The secondary objectives were to evaluate the characteristics of the supra-ventricular arrhythmias (delay in onset, duration, recurrent nature), incidence of others arrhythmia, symptoms, and prognostic implications of AF (hospitalization , need of curative anticoagulation, need for cardioversion and occurrence of neurological accident documented by imagery (ischemic stroke or TIA). The investigators also evaluated risk factors for occurrence of arrhythmia.

A total of 100 patients included during 1 year is expected

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women over the age of 18 to 60
  • Benefiting from the closure of the FOP percutaneously after a cryptogenic ischemic stroke or a TIA (indication validated during a multidisciplinary meeting with neurologists and cardiologists)

Exclusion criteria

  • Inability to perform a 24h ECG Holter
  • Pregnant or lactating women
  • Vulnerable people

Treatment and study plan

Primary outcomes

  1. occurrence of sustained supra-ventricular arrhythmia

    Time frame: the 24-hour post-intervention

    occurrence of sustained supra-ventricular arrhythmia (AF, atrial flutter) during the analysis the 24-hour Holter ECG performed post-intervention

  2. occurrence of sustained supra-ventricular arrhythmia

    Time frame: at 1 month

    occurrence of sustained supra-ventricular arrhythmia (AF, atrial flutter) during the analysis at 1 month (Holter ECG)

  3. occurrence of sustained supra-ventricular arrhythmia

    Time frame: at 6 month

    occurrence of sustained supra-ventricular arrhythmia (AF, atrial flutter) during the analysis at 6 month (Holter ECG)

  4. occurrence of sustained supra-ventricular arrhythmia

    Time frame: at 12 month

    occurrence of sustained supra-ventricular arrhythmia (AF, atrial flutter) during the analysis at 12 month (Holter ECG)

Secondary outcomes

  1. characteristics of these detected arrhythmias

    Time frame: 24 hours post-intervention to 12 months

    characteristics of these detected arrhythmias : time to onset

  2. characteristics of these detected arrhythmias

    Time frame: 24 hours post-intervention to 12 months

    characteristics of these detected arrhythmias : duration

  3. characteristics of these detected arrhythmias

    Time frame: 24 hours post-intervention to 12 months

    characteristics of these detected arrhythmias : recurrence

  4. symptoms related to the arrhythmia episode

    Time frame: 24 hours post-intervention to 12 months

    symptoms related to the arrhythmia episode

  5. hospitalization related to arrhythmia

    Time frame: 24 hours post-intervention to 12 months

    hospitalization related to arrhythmia

  6. occurrence of a neurological accident.

    Time frame: 24 hours post-intervention to 12 months

    occurrence of a neurological accident.

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Atrial Fibrillation on Holter Monitoring After Percutaneous Patent Foramen Ovale Closure : a Prospective Observational Study

Acronym: AFEPFO

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
Feb 28, 2020
Registry last updated
Apr 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.